Cleveland Biolabs Inc. Achieves Recovery From Neutropenia and Thrombocytopenia in Primates 48 Hours Post-Irradiation With Protectan CBLB502

BUFFALO, NY--(Marketwire - December 04, 2007) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a primate study demonstrating the efficacy of Protectan CBLB502 as a mitigator of hematopoietic (bone marrow/blood production) damage up to 48 hours post-radiation exposure.